 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
14 News |  |
- | lanopepden (GSK1322322) / GSK
Journal: Synthesis and characterisation of Co(iii) complexes of N-formyl hydroxylamines and antibacterial activity of a Co(iii) peptide deformylase inhibitor complex. (Pubmed Central) - Jan 21, 2021
Reaction of the N-formyl hydroxylamine-based GSK322 with [Co(tpa)Cl2]Cl afforded the corresponding Co(iii) chaperone complex of the peptide deformylase inhibitor, [Co(tpa)(GSK322-1H)](PF6)2. GSK322 and [Co(tpa)(GSK322-1H)](PF6)2 exhibited better Gram-positive activity than Gram-negative, where low MICs (1.56-6.25 μM) were determined for S. aureus strains, independent of their antibiotic susceptibility.
- lanopepden (GSK1322322) / GSK
Enrollment change, Trial withdrawal: A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women (clinicaltrials.gov) - Jan 28, 2015
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
GSK322 and [Co(tpa)(GSK322-1H)](PF6)2 exhibited better Gram-positive activity than Gram-negative, where low MICs (1.56-6.25 μM) were determined for S. aureus strains, independent of their antibiotic susceptibility. N=24 --> 0 | Not yet recruiting --> Withdrawn
- lanopepden (GSK1322322) / GSK
Enrollment change, Trial termination, Trial primary completion date: A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects (clinicaltrials.gov) - Jan 28, 2015
P1, N=12, Terminated, Sponsor: GlaxoSmithKline
N=24 --> 0 | Not yet recruiting --> Withdrawn N=36 --> 12 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Oct 2013; Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not seen that changed the risk: benefit profile and led to a termination
- lanopepden (GSK1322322) / GSK
Enrollment change, Trial withdrawal: A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers (clinicaltrials.gov) - Jan 28, 2015
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
N=36 --> 12 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Oct 2013; Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not seen that changed the risk: benefit profile and led to a termination N=40 --> 0 | Not yet recruiting --> Withdrawn
- | lanopepden (GSK1322322) / GSK
New P1 trial: A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women (clinicaltrials.gov) - Sep 29, 2013
P1, N=24, Not yet recruiting, Sponsor: GlaxoSmithKline
- lanopepden (GSK1322322) / GSK
Enrollment open: A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects (clinicaltrials.gov) - Aug 14, 2013
P1, N=36, Recruiting, Sponsor: GlaxoSmithKline
N=40 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | lanopepden (GSK1322322) / GSK
New P1 trial: A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects (clinicaltrials.gov) - Mar 24, 2013
P1, N=36, Recruiting, Sponsor: GlaxoSmithKline
- | lanopepden (GSK1322322) / GSK
New P1 trial: A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers (clinicaltrials.gov) - Feb 28, 2013
P1, N=40, Not yet recruiting, Sponsor: GlaxoSmithKline
- lanopepden (GSK1322322) / GSK
Trial completion: A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose (clinicaltrials.gov) - Oct 10, 2012
P1, N=5, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- lanopepden (GSK1322322) / GSK
New P1 trial: A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose (clinicaltrials.gov) - Aug 9, 2012
P1, N=5, Completed, Sponsor: GlaxoSmithKline
- | lanopepden (GSK1322322) / GSK
New P1 trial: A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects (clinicaltrials.gov) - Jul 22, 2012
P1, N=24, Completed, Sponsor: GlaxoSmithKline
- ||| lanopepden (GSK1322322) / GSK
New P1 trial: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects (clinicaltrials.gov) - May 31, 2012
P1, N=61, Completed, Sponsor: GlaxoSmithKline